Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Proteasome Modulator Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PSMB2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSMB2 Recombinant Protein (WT + Key Variants) High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Theoretical MW confirmed. Suitable for enzymatic activity assays. |
View PSMB2 Products |
| Gene Delivery | PSMB2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Overexpress WT or mutant for assembly studies. Endotoxin controlled. |
View PSMB2 Products |
| Benchmark Ab | Anti-PSMB2 Benchmark Antibody Recombinant positive control for Western blot and ELISA standardization. |
View PSMB2 Products |
| Validator | PSMB2 siRNA Set For target knockdown verification and specificity controls. |
View PSMB2 Products |
| Selectivity Panel | PSMB1, PSMB5, PSMB8 Recombinant Proteins Ortholog catalytic subunits for off-target liability screening. High purity (>95%), Sequence Verified by Mass Spec. |
View PSMB1 Products, View PSMB5 Products, View PSMB8 Products |
| Related Target: PSMB5 | Proteasome Beta 5 (Chymotrypsin-like) Primary target of first-gen inhibitors (Bortezomib); essential for selectivity profiling and synergistic pan-proteasome inhibition. |
View PSMB5 Products |
| Related Target: PSMB1 | Proteasome Beta 1 (Caspase-like) Co-assembles with PSMB2 in the 20S core; required for caspase-like activity assays and counter-screening. |
View PSMB1 Products |
| Related Target: PSMB8 | Immunoproteasome Subunit LMP7 Serves as selectivity counter-screen for autoimmune indication screening. |
View PSMB8 Products |
| Related Target: CRBN | Cereblon (E3 Ligase) Core component for PROTAC efficacy profiling; essential for targeted degradation modality developers. |
View CRBN Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subunit Selectivity Profiling (Trypsin-like vs Chymotrypsin-like vs Caspase-like) | Ortholog panel (PSMB1, PSMB2, PSMB5) with >95% purity; strictly verified by Mass Spectrometry for structural integrity. |
| Resistance Mutation Screening | Engineered mutant variant proteins available with strict sequence verification and controlled formulation. |
| Allosteric Site Mapping & PPI Validation | PSMB2 WT and surface-scanning mutant panel; >95% purity; Theoretical MW confirmed by mass spec. |
| 20S Reconstitution & Assembly Fidelity | Endotoxin-controlled (<1 EU/µg) monomeric PSMB2 for complex reassembly assays. |
| Cell-based Activity Validation | Active enzyme format; validated for fluorogenic substrate cleavage assays (Z-GGR-AMC). |
| Cross-species Preclinical Evaluation | Human/Mouse/Rat ortholog proteins available with identical purity standards. |
| False Positives & Lack of Specificity Controls | Sequence-specific siRNA included for target specificity confirmation; Benchmark Abs for reproducible assay standardization. |
Live PSMB2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The proteasome inhibitor landscape is evolving from broad-spectrum inhibition (simultaneously targeting PSMB2, PSMB1, and PSMB5) to next-generation selective modulation and targeted protein degradation. First-generation therapies like bortezomib and carfilzomib primarily inhibit the chymotrypsin-like activity of PSMB5, but clinical resistance through compensatory upregulation of other subunits (including PSMB2 trypsin-like activity) has emerged. Co-targeting PSMB2 alongside PSMB5/PSMB1 is now recognized as a critical strategy to overcome resistance and improve safety profiles, as peripheral neuropathy driven by broad PSMB5 inhibition remains a major dose-limiting toxicity. Concurrently, the rise of PROTACs and molecular glues has renewed interest in PSMB2 kinetics within the 26S holoenzyme context, shifting assay requirements from simple enzymatic inhibition to complex substrate processing evaluation. The next wave of R&D is increasingly focused on dual-subunit and pan-proteasome inhibitors (e.g., marizomib), as well as immunoproteasome-selective approaches for autoimmune indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Inhibitors | Takeda, Amgen, Celgene (BMS) | Multiple Myeloma, Solid Tumors | Selectivity panel (PSMB1/2/5/8) for reduced neurotoxicity screening; subunit-specific fluorogenic assays. |
| Targeted Protein Degradation (PROTACs) | Arvinas, Kymera Therapeutics, Nurix Therapeutics | Solid Tumors, Refractory Malignancies | Downstream effector validation; need siRNA and Benchmark Abs for knockdown/degradation proof; functional 26S proteasome assembly. |
| Covalent Inhibitors | Onyx Pharmaceuticals, Sanofi | Relapsed/Refractory Hematological Cancers | Binding kinetic analysis; need accurately quantified, structural-integrity-preserved proteins for SPR/BLI. |
| Immunoproteasome Inhibitors | Bristol Myers Squibb, Kezar Life Sciences | Autoimmune Diseases, Oncology | PSMB2 vs PSMB8/PSMB9 selectivity assays; endotoxin-controlled proteins. |
| Proteasome Activators | Academic Consortia | Neurodegeneration, Proteinopathies | Enzymatic activity assays with fluorogenic substrates; cross-species orthologs. |
Molecular Differentiation & Assay Strategy
To develop best-in-class proteasome modulators, key molecular differentiation factors include: (1) Selectivity: >100-fold preference for PSMB2 over PSMB5 to minimize neurotoxicity; (2) Binding Kinetics: slow off-rate for sustained inhibition; (3) Cell Permeability: must reach cytosolic 26S proteasome; (4) Immunoproteasome Context: activity difference between constitutive (PSMB2) and immunoproteasome (PSMB8).
Recommended assay strategy: Combine subunit-specific fluorogenic substrates (Z-GGR-AMC for trypsin-like, Suc-LLVY-AMC for chymotrypsin-like, Z-LLE-AMC for caspase-like) with high-purity recombinant proteins from TarMart. Include cell-based functional assays using PSMB2 ORF lentivirus and siRNA knockdown to confirm on-target effects. For resistance profiling, prepare PSMB2 clinical mutant recombinant proteins and test IC50 shifts.
Related Target Recommendation for Cross-Sell
For a complete pan-proteasome and ubiquitin-proteasome pathway evaluation system, the following targets are recommended for cross-selling:
- PSMB5: Mandatory control for chymotrypsin-like activity.
- PSMB1: Required for caspase-like activity profiling.
- PSMB8: Essential for immunoproteasome selectivity.
- CRBN: Core E3 ligase for PROTAC developers.
- VHL: Alternative E3 ligase for targeted degradation modalities.
TarMart provides a "Selectivity Panel Bundle" concept—each customer purchasing PSMB2 should also obtain PSMB5 and PSMB8 as controls, which is a standard requirement for regulatory and publication purposes.